Skip to main content
. 2022 Oct 17;12(17):7371–7389. doi: 10.7150/thno.74075

Figure 9.

Figure 9

Serum CCL5 level correlated with clinical response. (A) CCL5 expression levels in melanoma patients with SD/PD receiving OH2 monotherapy. (B) CCL5 expression levels in melanoma patients with PR receiving OH2 monotherapy. (C) CCL5 expression levels in colorectal cancer patients with SD/PD receiving OH2 combined with PD-1 antibody. (D) CCL5 expression levels in colorectal cancer patients with PR receiving OH2 combined with PD-1 antibody.